A Wortmannin-Cetuximab as a Double Drug

 
Thumbnail
View/Open
Author
Smith, R. Adam
Yuan, Hushan
Weissleder, Ralph
Cantley, Lewis C.
Josephson, Lee
Published Version
https://doi.org/10.1021/bc900176a
Metadata
Show full item record
Citation
Smith, R. Adam, Hushan Yuan, Ralph Weissleder, Lewis C. Cantley, and Lee Josephson. 2009. “A Wortmannin−Cetuximab as a Double Drug.” Bioconjugate Chemistry 20 (11): 2185–89. https://doi.org/10.1021/bc900176a.
Abstract
Double drugs are obtained when two pharmacologically active entities are covalently joined to improve potency. We conjugated the viridin Wm with a self-activating linkage to cetuximab and demonstrated the retention of immunoreactivity by the conjugate. Though cetuximab lacked a growth inhibitory activity against A549 cells, the Wm-cetuximab conjugate had an antiproliferative IC(50) of 155 nM in vitro. The chemistry of attaching a self-releasing Wm to clinically approved antibodies is general and, in selected instances, may yield antibody-based double drugs with improved efficacy.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41384272

Collections